Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01KKI
|
|||
| Former ID |
DIB015597
|
|||
| Drug Name |
SGN-CD33A
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1] | |
| Company |
Seattle genetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | . | [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.